



340B Notice Regarding Limited Distribution Plan for Imbruvica (*ibrutinib*)

August 17, 2016

This notice provides information for 340B covered entities about how to acquire Imbruvica (*ibrutinib*) at the 340B ceiling price.

Imbruvica (*ibrutinib*) is a highly specialized orphan oral oncologic therapy. Specifically, it is a kinase inhibitor indicated for the treatment of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma with or without 17p deletion, Waldenström's macroglobulinemia, and mantle cell lymphoma.

In order to ensure that patients being treated with Imbruvica receive the best possible care and to increase optimal therapeutic adherence, Pharmacyclics has developed a limited distribution plan designed to achieve these goals. All pharmacies – 340B and otherwise – are subject to this plan equally.

If your pharmacy (a) is an oncology-specific facility, (b) employs on-site prescribing oncologists, and (c) dispenses to patients of record of your facility, we invite you to join our network of pharmacies served by our specialty distributor partners McKesson Specialty Health, Oncology Supply, ASD Healthcare and McKesson Plasma & Biologics. In-network 340B covered entities are able to order Imbruvica from these specialty distributors at the 340B ceiling price. To apply, please call 1-877-877-3536. Operators are available Monday through Friday, 8 am-8 pm ET.

If your pharmacy does not qualify for inclusion in our network, or if you choose not to apply for or join our network, you can still access Imbruvica through one of our specialty pharmacy partners: Avella Specialty Pharmacy, Biologics, Diplomat Specialty Pharmacy or Onco360. These specialty pharmacies will fill scripts from your institution at the 340B ceiling price, and ship Imbruvica directly to your patients' homes. Contact information for these specialty pharmacies can be found at www.imbruvicahcp.com/you-i-support-and-resources.

Pharmacyclics is committed to both patient safety and compliance with the rules of the 340B program. Our limited distribution plan attempts to address both concerns. If you have any questions about this plan, or any difficulty obtaining Imbruvica for your patients, please contact Pharmacyclics at 1-877-877-3536.

* * *